AIMMS researchers successfully apply for compound screening at the European Lead Factory

Joen Luirink and Maurice Steenhuis (PhD-student) from the Molecular Microbiology group successfully applied for compound screening at the European Lead Factory (ELF).

07/13/2020 | 11:16 AM

ELF is a pan-European consortium that is funded by the Innovative Medicines Initiative (IMI) with the aim to develop novel drugs. Luirink is interested in the essential β-barrel assembly machinery (BAM complex) in the outer membrane of Gram-negative bacteria as a target for a novel class of antibiotics. Steenhuis, a PhD-student in Luirink’s lab funded by an NWO AIMMS STAR grant, developed high-throughput phenotypic stress-based reporter assays that respond to decreased BAM activity, of which an article has recently been published. The assays will now be used to screen a collection of 500,000 chemical compounds, which may result in novel lead compounds as a starting point for antibiotic discovery.

Overview of screening assay
compound screening